- ROUNDTABLE: Pharmacy’s future in sync with technology
- ROUNDTABLE: Improving patient outcomes, controlling costs with OTCs
- Novartis Consumer Health's return to shelf on track, Theraflu relaunching next
- Sandoz starts late-stage trial of Humira biosimilar
- NACDS, NCPA, GPhA express support for Drug Quality and Security Act
NEW YORK — Generic drug maker Sandoz has launched an authorized generic version of a drug used to treat hypertension.
The generics division of Swiss drug maker Novartis announced the introduction of valsartan and hydrochlorothiazide tablets, a generic version of Novartis' Diovan HCT. Novartis will continue marketing the branded version of the drug, which had sales of $2.3 billion in 2011 together with Diovan (valsartan).
"We are pleased to offer a high-quality generic version of this leading treatment to the tens of millions of Americans working to control their blood pressure," Sandoz president Don DeGolyer said. "As part of the Novartis Group, which has a leading global position in both branded and generic medicines, we are uniquely positioned to maximize access and choice for patients and healthcare professionals."
An authorized generic is a branded drug sold under its generic name at a reduced price.